| Document |
Document Title |
|
WO/2021/174170A9 |
The present disclosure features compounds and related compositions that, inter alia, modulate nucleic acid splicing, e.g., splicing of a pre-mRNA, as well as methods of use thereof.
|
|
WO/2022/188819A1 |
The present invention relates to an SOS1 proteolysis modulator, a preparation method therefor and the application thereof. In particular, the compound of the present invention has a structure represented by formula (I). Further disclosed...
|
|
WO/2022/192162A1 |
Pharmaceutical compositions of the invention comprise heteroaromatic compounds having a disease-modifying action in the treatment of fungal infections and diseases associated with fungal infection.
|
|
WO/2022/192533A1 |
Disclosed herein are kinase inhibitory compounds, such as a receptor¬ interacting protein-1 (RIP1) kinase inhibitor compounds of formula (I), as well as pharmaceutical compositions and combinations comprising such inhibitory compounds. ...
|
|
WO/2022/192431A1 |
The present disclosure provides a compound represented by structural formula (1-0): or a pharmaceutically acceptable salt thereof useful for treating a cancer.
|
|
WO/2022/188841A1 |
Disclosed in the present invention are a histone deacetylase inhibitor and an application thereof. Specifically, provided are a compound represented by general formula (I), a pharmaceutically acceptable salt thereof, a preparation method...
|
|
WO/2022/192430A1 |
The present disclosure provides GLP-1R agonists of formula (I), and compositions, methods, and kits thereof. Such compounds are generally useful for treating a GLP-1R mediated disease or condition in a human.
|
|
WO/2022/189392A1 |
The present invention relates to new 2,3-dihydro-1H-pyrrolo[3,2-b]pyridine derivatives of formula (I): as sigma ligands having a great affinity for sigma receptors, especially sigma-1 (σ1) and/or sigma-2 (σ2) receptors, as well as to t...
|
|
WO/2022/187633A1 |
Compositions and methods for control and/or modification of endogenous protein acetylation are described. The compositions are directed to heterobifunctional molecules having protein and enzyme binding moieties linked together by an orga...
|
|
WO/2022/185058A1 |
Compounds of the formula (I) and pharmaceutically acceptable salts thereof: (I) wherein the substituents are defined in the specification. The compounds are hyperpolarisation activated cyclic-nucleotide modulated ion channel 2 (HCN2) inh...
|
|
WO/2022/187266A1 |
This application relates to novel substituted bicyclic aza-heterocycles and analogues, their manufacture, pharmaceutical compositions comprising them, and their use as medicaments for treating a disease associated with mammalian RAS (Rat...
|
|
WO/2022/187206A1 |
Disclosed herein are novel dual-target compounds that bind at both the mu-opioid receptor (MOR) and dopamine D3 receptors (D3R) to provide MOR-mediated analgesia, while minimizing addictive liability through D3R antagonism/partial agonis...
|
|
WO/2022/187203A1 |
Provided are compounds of Formula (I): (I); and pharmaceutically acceptable salts and compositions thereof, which are useful for treating a variety of conditions associated with PPARG.
|
|
WO/2022/186133A1 |
In agricultural and horticultural crop production, there is still a great amount of damage due to pests and the like. Thus, the present invention addresses the problem of providing a novel agricultural/horticultural pesticide from the vi...
|
|
WO/2022/187200A1 |
Provided herein are compounds and methods for the treatment of cancer. The methods include administering to a subject in need a therapeutically effective amount of a of RNR inhibitor disclosed herein.
|
|
WO/2022/187178A1 |
The present disclosure describes compounds of Formula (I) and Formula (II) and stereoisomers, tautomers, and pharmaceutically acceptable salts or solvates thereof, wherein all of the variables are as defined herein. This disclosure also ...
|
|
WO/2022/186512A1 |
The present invention relates to: a pyridinyl pyrazole derivative or a pharmaceutically acceptable salt thereof; and a composition and the like for preventing or treating protein kinase-related diseases, containing, as an active ingredie...
|
|
WO/2022/184130A1 |
Provided are a compound as represented by formula I, or a deuterated compound thereof or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, and the use thereof in the preparation of a medicament for treating a disease.
|
|
WO/2022/184000A1 |
A novel imidazole compound serving as a TGF-β inhibitor, and in particular a TGFβR-1 inhibitor, a pharmaceutical composition comprising the compound, and a use of the compound and the composition in the prevention and/or treatment of T...
|
|
WO/2022/185055A1 |
Compounds of the formula (I) and pharmaceutically acceptable salts thereof: (I) wherein the substituents are defined in the specification. The compounds are hyperpolarisation activated cyclic-nucleotide modulated ion channel 2 (HCN2) inh...
|
|
WO/2022/187527A1 |
The present disclosure provides certain quinazoline nitrile derivatives that inhibit certain K-Ras proteins and are therefore useful for the treatment of cancers mediated by such proteins. Also provided are pharmaceutical compositions co...
|
|
WO/2022/184152A1 |
A compound having HPK1 inhibitory activity as shown in formula (IA) or (IC), and a pharmaceutically acceptable salt, a stereoisomer, a solvate or a prodrug thereof, and a pharmaceutical composition containing the compound, and use of sam...
|
|
WO/2022/186362A1 |
To provide a method for producing a pyrazole compound suited to mass production. The present invention relates to a method for producing a pyrazole compound represented by general formula (2) (in the formula, R1 and R2 have the same me...
|
|
WO/2022/184849A1 |
Compounds of formula (I)
|
|
WO/2022/182547A1 |
This disclosure is directed to agonists of the apelin receptor (APJ) and uses of such agonists.
|
|
WO/2022/179528A1 |
Provided are TNIK and/or MAP4K4 kinases inhibitors for the treatment of disease. In one aspect, disclosed herein are kinase inhibitors having a structure of Formula (A), (A*), (I), (IIA), or (IIB). Further described herein are pharmaceut...
|
|
WO/2022/179584A1 |
Disclosed are a compound as represented by formula (I), a stereoisomer thereof or a pharmaceutically acceptable salt thereof, and the use thereof in the preparation of a medicament for treating EZH2-mediated diseases.
|
|
WO/2022/183034A1 |
The disclosure relates to compounds of the formulae (I), (II), (lla), (III), (IV), and (IVa) and pharmaceutically acceptable salts, polymorphs, prodrugs, solvates or clathrates thereof, and pharmaceutical compositions comprising such com...
|
|
WO/2022/181157A1 |
Provided are a compound that improves the performance of an organic EL element, an organic electroluminescent element having improved element performance, and an electronic device including such an organic electroluminescent element, the...
|
|
WO/2022/181933A1 |
The present specification relates to a heterocyclic compound, an organic light-emitting device comprising same, a manufacturing method therefor, and a composition for an organic layer.
|
|
WO/2022/182205A1 |
The present invention provides a novel pyrazole derivative compound represented by chemical formula I, a stereoisomer thereof, a solvate thereof, an isotopic variant thereof, a tautomer thereof, or a pharmaceutically acceptable salt ther...
|
|
WO/2022/179578A1 |
A compound containing a sulfinylpyridine structure. Specifically disclosed is the compound of formula (I) or a pharmaceutically acceptable salt thereof.
|
|
WO/2022/179529A1 |
Provided are TNIK and/or MAP4K4 kinases inhibitors for the treatment of disease. In one aspect, disclosed herein are kinase inhibitors having a structure of Formulas (A), (A*), (I), (II), (AA), (B), (C), (D), (B*), (C*) and (D*). Further...
|
|
WO/2022/178592A1 |
The disclosure provides methods for the solid phase synthesis of glutamate-urea-lysine derived (GUL derived) prostate-specific membrane antigen (PSMA) targeting conjugates. The disclosure also relates to key intermediates of this process...
|
|
WO/2022/174796A1 |
Disclosed are a pyrimidine compound represented by formula (1) as a Wee-1 inhibitor, a preparation method therefor, and an application of the compound represented by formula (1) and various isomers, crystal forms, pharmaceutically accept...
|
|
WO/2022/177974A1 |
Described herein are crystalline forms of 4-[(3S)-3-aminopyrrolidin-1-yl]-6-cyano-5-(3,5-difluoropheny
l)-N-[(2S)-1,1,1-trifluoropropan-2-yl]pyridine-3-carboxamide
, uses of such crystalline forms in the preparation of pharmaceutical com...
|
|
WO/2022/174765A1 |
Disclosed in the present invention is a fused ring compound as a Wee-1 inhibitor. Specifically, the present invention relates to a compound represented by general formula (1), a preparation method therefor, and a use of the compound of g...
|
|
WO/2022/175675A1 |
The present invention provides compounds of formula (I): compositions comprising such compounds; the use of such compounds in medicine; and methods of treating patients with such compounds; wherein A, W, V, Z, U, X, Y and B are as define...
|
|
WO/2022/177988A1 |
Provided herein are methods and compositions for the treatment of hyperinsulinism
|
|
WO/2022/175889A1 |
The present invention relates to a method for the enantioselective preparation of a compound of formula (I).
|
|
WO/2022/176961A1 |
Disclosed is a compound represented by formula (1). In formula (1), n represents an integer of 0-5. Q1, Q2, Q3, and Q4 represent a moiety selected from group A, a moiety selected from group B, a moiety represented by formula (C1), or the...
|
|
WO/2022/176954A1 |
Disclosed is a radioactive metal complex. The radioactive metal complex has a radioactive metal element and a ligand derived from a compound represented by formula (1). The radioactive metal element is 89Zr or 225Ac. (1) [In formula (1...
|
|
WO/2022/175982A1 |
The present invention discloses a process for preparation of Batefenterol of Formula (I) or pharmaceutically acceptable salts thereof, and its intermediates by epoxidation. The process involves preparation of the intermediate compound of...
|
|
WO/2022/177927A1 |
The present disclosure relates to an anhydrous crystalline form (I) of omecamtiv mecarbil (CK-1827452, methyl 4-[[2-fluoro-3-[(6-methylpyridin-3-y])carbamoylamino]phenyl]
methyl]piperazinyl- carboxylate) dihydrobromide salt 2 HBr, charac...
|
|
WO/2022/171265A1 |
The present invention describes compounds modulating the function of mitochondrial complex I (NADH-quinone oxidoreductase) having formula (I).
|
|
WO/2022/173805A1 |
The present application discloses novel compounds, pharmaceutical compositions containing these compounds and methods of inducing degradation of a protein, comprising contacting the protein with an effective amount of a compound of the d...
|
|
WO/2022/171118A1 |
A class of compounds as represented by a formula (I) or stereoisomers, geometric isomers, tautomers, hydrates, solvates, isotopically labeled analogs, prodrugs or pharmaceutically acceptable salts thereof, and the use thereof. Each group...
|
|
WO/2022/171018A1 |
The present invention relates to a substituted benzopyrimidine or pyridopyrimidine amine inhibitor, and a preparation method therefor and the use thereof. Specifically, the compound of the present invention has a structure as shown in fo...
|
|
WO/2022/171896A1 |
The present invention is directed to methods for selecting (solution) conditions to introduce an analyte guest compound into a crystalline polynuclear metal complex. The selected (solution) conditions can be used in a method for introduc...
|
|
WO/2022/173849A1 |
The present disclosure provides a compound of Formula (I) a pharmaceutically acceptable salt, or a stereoisomer and their use in, e.g. treating a condition, disease or disorder modulated at least in part by CCR6. This disclosure also fea...
|
